Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
232.1 INR | +2.34% | -3.77% | +79.51% |
Valuation
Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capitalization 1 | 536.9 | 370.5 | 196 | 505.5 | 625.1 | 340.5 |
Enterprise Value (EV) 1 | 610.9 | 417.9 | 177.2 | 428.8 | 710.8 | 386.8 |
P/E ratio | 15.2 x | 8.42 x | 4.83 x | 7.04 x | 22 x | 13.9 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 1.32 x | 0.79 x | 0.45 x | 0.93 x | 1.23 x | 0.64 x |
EV / Revenue | 1.5 x | 0.89 x | 0.4 x | 0.79 x | 1.4 x | 0.73 x |
EV / EBITDA | 9.8 x | 6.11 x | 2.88 x | 3.81 x | 15.4 x | 8.81 x |
EV / FCF | 54.1 x | 30.4 x | 3.29 x | 9.01 x | -4.13 x | -8.98 x |
FCF Yield | 1.85% | 3.29% | 30.4% | 11.1% | -24.2% | -11.1% |
Price to Book | 4.14 x | 2.13 x | 0.91 x | 1.77 x | 1.98 x | 1 x |
Nbr of stocks (in thousands) | 6,233 | 6,233 | 6,233 | 6,233 | 6,233 | 6,233 |
Reference price 2 | 86.15 | 59.45 | 31.45 | 81.10 | 100.3 | 54.64 |
Announcement Date | 8/13/18 | 8/10/19 | 9/4/20 | 8/6/21 | 6/24/22 | 5/16/23 |
Income Statement Evolution (Annual data)
Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net sales 1 | 407.9 | 468.2 | 437.9 | 542.5 | 508.7 | 528.9 |
EBITDA 1 | 62.33 | 68.42 | 61.59 | 112.4 | 46.25 | 43.93 |
EBIT 1 | 53.02 | 58.33 | 51.36 | 102.1 | 36.08 | 33.18 |
Operating Margin | 13% | 12.46% | 11.73% | 18.81% | 7.09% | 6.27% |
Earnings before Tax (EBT) 1 | 47.27 | 60.69 | 56.42 | 105 | 38.74 | 34.46 |
Net income 1 | 35.3 | 43.99 | 40.54 | 71.8 | 28.45 | 24.42 |
Net margin | 8.65% | 9.4% | 9.26% | 13.23% | 5.59% | 4.62% |
EPS 2 | 5.660 | 7.059 | 6.505 | 11.52 | 4.560 | 3.918 |
Free Cash Flow 1 | 11.28 | 13.73 | 53.84 | 47.58 | -172.2 | -43.08 |
FCF margin | 2.77% | 2.93% | 12.3% | 8.77% | -33.85% | -8.14% |
FCF Conversion (EBITDA) | 18.1% | 20.07% | 87.42% | 42.33% | - | - |
FCF Conversion (Net income) | 31.97% | 31.21% | 132.8% | 66.27% | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 8/13/18 | 8/10/19 | 9/4/20 | 8/6/21 | 6/24/22 | 5/16/23 |
Balance Sheet Analysis
Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net Debt 1 | 74 | 47.4 | - | - | 85.7 | 46.3 |
Net Cash position 1 | - | - | 18.8 | 76.6 | - | - |
Leverage (Debt/EBITDA) | 1.187 x | 0.6921 x | - | - | 1.852 x | 1.053 x |
Free Cash Flow 1 | 11.3 | 13.7 | 53.8 | 47.6 | -172 | -43.1 |
ROE (net income / shareholders' equity) | 31.5% | 29% | 20.8% | 28.7% | 9.47% | 7.43% |
ROA (Net income/ Total Assets) | 11.6% | 11.4% | 9.75% | 17.2% | 4.66% | 3.74% |
Assets 1 | 304.7 | 385.4 | 415.7 | 417.8 | 610.9 | 653.2 |
Book Value Per Share 2 | 20.80 | 27.90 | 34.50 | 45.90 | 50.60 | 54.90 |
Cash Flow per Share 2 | 2.880 | 5.390 | 8.080 | 17.40 | 8.360 | 2.870 |
Capex 1 | 18 | 16.2 | 6.72 | 3.75 | 46.1 | 40.7 |
Capex / Sales | 4.41% | 3.45% | 1.54% | 0.69% | 9.06% | 7.7% |
Announcement Date | 8/13/18 | 8/10/19 | 9/4/20 | 8/6/21 | 6/24/22 | 5/16/23 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
+79.51% | 16.97M | |
+32.09% | 693B | |
+29.39% | 584B | |
-1.34% | 372B | |
+20.34% | 332B | |
+7.39% | 294B | |
+14.25% | 239B | |
-3.03% | 211B | |
+10.02% | 210B | |
+8.49% | 168B |
- Stock Market
- Equities
- AUROLAB6 Stock
- Financials Auro Laboratories Limited